Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology

By sjmartinez • March 15, 2025

Antonarelli G, Pérez-García JM, Gion M, Rugo H, Schmid P, Bardia A, Hurvitz S, Harbeck N, Tolaney SM, Curigliano G, Llombart-Cussac A, Cortés J. Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology. Ann Oncol. 2025 Mar 12:S0923-7534(25)00111-5. doi: 10.1016/j.annonc.2025.03.005. Epub ahead of print. PMID: 40086733.

Tags: clinical trials, Hematology/Oncology, Medical Oncology, Publications, Regulatory Approval, Strategic Design

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer

Herbst RS, John T, Grohé C, Goldman JW, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn MJ, Kowalski DM, Pérol[...]

Microcytosis Merits Evaluation: A Case Report of Hemoglobin S With Hereditary Persistence of Fetal Hemoglobin (HbS-HPFH Syndrome)

Daniel CE, Bejjani A. Microcytosis Merits Evaluation: A Case Report of Hemoglobin S With Hereditary Persistence of Fetal Hemoglobin (HbS-HPFH Syndrome). Cureus. 2025 Feb 10;17(2):e78827.[...]

Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial

Haddad R, Fayette J, Teixeira M, Prabhash K, Mesia R, Kawecki A, Dechaphunkul A, Dinis J, Guo Y, Masuda M, Hsieh CY, Ghi MG, Vaz[...]